The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience

Leuk Lymphoma. 2022 Jul;63(7):1738-1741. doi: 10.1080/10428194.2022.2038374. Epub 2022 Feb 11.

Authors

Rory Bennett¹, Henry Chan^{1

2}, Ross Henderson¹, Eileen Merriman^{1

2}, Merit Hanna¹, Anna Elinder-Camburn¹, David Simpson¹

Affiliations

¹ Department of Haematology, Waitemata District Health Board, Takapuna, New Zealand.
² Faculty of Medical and Health Sciences, The University of Auckland, Grafton, New Zealand.

PMID: 35147474
DOI: 10.1080/10428194.2022.2038374

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Dexamethasone / therapeutic use
Humans
Lopinavir / therapeutic use
Multiple Myeloma* / diagnosis
Multiple Myeloma* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Oligopeptides
Ritonavir / therapeutic use

Substances

Oligopeptides
Lopinavir
carfilzomib
Dexamethasone
Ritonavir